PARP inhibitors and the treatment of breast cancer: Beyond BRCA1/2?

Kristine M. Frizzell, W. Lee Kraus

Research output: Contribution to journalEditorialpeer-review

29 Scopus citations


Poly(ADP-ribose) polymerase (PARP) inhibitors have been explored as therapeutic agents for the treatment of hereditary breast and ovarian cancers harboring mutations in BRCA1 or BRCA2 In a new study, Inbar-Rozensal and colleagues show that phenanthridine-derived PARP inhibitors promote cell cycle arrest and cell death in breast cancer cells lacking BRCA1 and BRCA2 mutations and prevent the growth of tumors from xenografts of these cells in immunocompromised mice. These results suggest a potential broader utility of PARP-1 inhibitors in the treatment of breast cancer, although further mechanistic studies are needed.

Original languageEnglish (US)
Article number111
JournalBreast Cancer Research
Issue number6
StatePublished - Nov 26 2009

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'PARP inhibitors and the treatment of breast cancer: Beyond BRCA1/2?'. Together they form a unique fingerprint.

Cite this